Amicus Therapeutics Management

Management Kriterienprüfungen 3/4

Amicus Therapeutics' CEO ist Brad Campbell , ernannt in Jan 2015, hat eine Amtszeit von 9.42 Jahren. Die jährliche Gesamtvergütung beträgt $8.20M , bestehend aus 8.5% Gehalt und 91.5% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.3% der Aktien des Unternehmens, im Wert von $8.66M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 7.3 Jahre bzw. 6 Jahre.

Wichtige Informationen

Brad Campbell

Geschäftsführender

US$8.2m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	8.5%
Amtszeit als Geschäftsführer	9.5yrs
Eigentum des Geschäftsführers	0.3%
Durchschnittliche Amtszeit des Managements	7.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	6.1yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Brad Campbell im Vergleich zu den Einnahmen von Amicus Therapeutics verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-US$147m
Dec 31 2023	US$8m	US$699k	-US$152m
Sep 30 2023	n/a	n/a	-US$174m
Jun 30 2023	n/a	n/a	-US$185m
Mar 31 2023	n/a	n/a	-US$204m
Dec 31 2022	US$9m	US$591k	-US$237m
Sep 30 2022	n/a	n/a	-US$264m
Jun 30 2022	n/a	n/a	-US$281m
Mar 31 2022	n/a	n/a	-US$270m
Dec 31 2021	US$5m	US$551k	-US$250m
Sep 30 2021	n/a	n/a	-US$239m
Jun 30 2021	n/a	n/a	-US$252m
Mar 31 2021	n/a	n/a	-US$254m
Dec 31 2020	US$5m	US$516k	-US$277m
Sep 30 2020	n/a	n/a	-US$295m
Jun 30 2020	n/a	n/a	-US$293m
Mar 31 2020	n/a	n/a	-US$325m
Dec 31 2019	US$4m	US$501k	-US$356m
Sep 30 2019	n/a	n/a	-US$345m
Jun 30 2019	n/a	n/a	-US$442m
Mar 31 2019	n/a	n/a	-US$419m
Dec 31 2018	US$3m	US$468k	-US$349m
Sep 30 2018	n/a	n/a	-US$340m
Jun 30 2018	n/a	n/a	-US$293m
Mar 31 2018	n/a	n/a	-US$279m
Dec 31 2017	US$2m	US$450k	-US$284m

Vergütung im Vergleich zum Markt: BradDie Gesamtvergütung ($USD8.20M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt UK ($USD2.46M).

Entschädigung vs. Einkommen: BradDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Brad Campbell (48 yo)

9.5yrs

Amtszeit

US$8,202,366

Vergütung

Mr. Bradley L. Campbell, also known as Brad, MBA, serves as Director of Gennao Bio, Inc. since March 2022. He serves as Director of Alliance for Regenerative Medicine. He served as Chief Operating Officer...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Bradley Campbell	CEO, President & Director	9.5yrs	US$8.20m	0.30% $ 8.7m
Simon Nicolas Harford	Chief Financial Officer	less than a year	US$3.27m	keine Daten
Ellen Rosenberg	Chief Legal Officer & Corporate Secretary	8.4yrs	US$4.08m	0.065% $ 1.9m
David Clark	Chief People Officer	5.8yrs	US$3.21m	0.047% $ 1.4m
Jeffrey Castelli	Chief Development Officer	no data	US$3.67m	0.081% $ 2.3m
Samantha Prout	Chief Accounting Officer & Controller	6.3yrs	keine Daten	0.025% $ 725.3k
Jill Weimer	Chief Science Officer	no data	keine Daten	keine Daten
Andrew Faughnan	Senior Director of Investor Relations	no data	keine Daten	keine Daten
Patrik Florencio	Global Chief Compliance & Risk Officer	8.9yrs	keine Daten	keine Daten
Diana Moore	Head of Global Corporate Communications	no data	keine Daten	keine Daten
Jayne Gershkowitz	Chief Patient Advocate	8.8yrs	keine Daten	keine Daten
Julie Yu	Chief Program Officer	4.2yrs	keine Daten	keine Daten

7.4yrs

Durchschnittliche Betriebszugehörigkeit

54.5yo

Durchschnittliches Alter

Erfahrenes Management: 0HF9Das Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (7.3 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Bradley Campbell	CEO, President & Director	6.1yrs	US$8.20m	0.30% $ 8.7m
Burke Whitman	Independent Director	5.1yrs	US$391.25k	0.026% $ 762.7k
Michael Kelly	Independent Director	3.6yrs	US$391.25k	0.0099% $ 288.5k
Glenn Sblendorio	Independent Director	18.1yrs	US$407.07k	0.025% $ 735.7k
Margaret McGlynn	Independent Director	14.8yrs	US$401.25k	0.017% $ 497.5k
Craig Wheeler	Independent Director	8.1yrs	US$398.50k	0.015% $ 429.5k
Michael Raab	Chairman & Lead Independent Director	20.5yrs	US$426.25k	0.025% $ 735.7k
Eiry Roberts	Independent Director	3.1yrs	US$390.00k	0.0081% $ 235.9k
Lynn Bleil	Independent Director	5.8yrs	US$397.50k	0.025% $ 717.1k

6.1yrs

Durchschnittliche Betriebszugehörigkeit

64yo

Durchschnittliches Alter

Erfahrener Vorstand: 0HF9Die Vorstandsmitglieder gelten als erfahren (6 Jahre durchschnittliche Amtszeit).

Amicus Therapeutics Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

Amicus Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Insufficient new directors

Amicus Therapeutics Announces Executive Changes

Amicus Therapeutics, Inc. Announces Chief Financial Officer Changes

Amicus Therapeutics, Inc. Announces Retirement of Daphne Quimi as Chief Financial Officer

Amicus Therapeutics, Inc. Appoints Samantha Prout as Chief Accounting Officer and Controller

Recent updates

Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings released: US$0.16 loss per share (vs US$0.18 loss in 1Q 2023)

Amicus Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Amicus Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Forecast breakeven date pushed back to 2025

Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

Full year 2023 earnings released: US$0.51 loss per share (vs US$0.82 loss in FY 2022)

Amicus Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 28, 2024

Forecast to breakeven in 2024

Amicus Therapeutics, Inc. Provides Revenue Guidance for the Year 2024

Insufficient new directors

Amicus Therapeutics Announces Executive Changes

Forecast to breakeven in 2024

Third quarter 2023 earnings released: US$0.073 loss per share (vs US$0.12 loss in 3Q 2022)

Amicus Therapeutics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Amicus Therapeutics, Inc. announced that it has received $29.999985 million in funding

New minor risk - Share price stability

Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease

New Paradigm Therapeutics, Inc. acquired worldwide rights of SD-101 from Amicus Therapeutics, Inc. (NasdaqGM:FOLD).

Amicus Therapeutics, Inc. Announces Chief Financial Officer Changes

Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom

Second quarter 2023 earnings released: US$0.15 loss per share (vs US$0.21 loss in 2Q 2022)

Amicus Therapeutics, Inc. Announces Retirement of Daphne Quimi as Chief Financial Officer

New minor risk - Share price stability

Amicus Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Amicus Therapeutics, Inc. Appoints Samantha Prout as Chief Accounting Officer and Controller

Amicus Therapeutics Inc. Announces Approval and Launch of New Pompe Disease Therapy in the European Union

Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings released: US$0.18 loss per share (vs US$0.30 loss in 1Q 2022)

Full year 2022 earnings released: US$0.82 loss per share (vs US$0.92 loss in FY 2021)

Amicus Therapeutics, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Amicus Therapeutics, Inc. Provides Revenue Guidance for the Year 2023

Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease

Third quarter 2022 earnings released: US$0.12 loss per share (vs US$0.19 loss in 3Q 2021)

Amicus Therapeutics, Inc. Provides Revenue Guidance for the Full-Year of 2022

Amicus Therapeutics, Inc. Announces U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease

Amicus Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Executive Chairman recently sold US$112k worth of stock

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.19 loss in 2Q 2021)

Amicus Therapeutics, Inc. Provides Guidance for 2022

Amicus Therapeutics, Inc. Appoints Bradley L. Campbell as Chief Executive Officer

Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA

First quarter 2022 earnings released: US$0.30 loss per share (vs US$0.25 loss in 1Q 2021)

Amicus Therapeutics, Inc. Provides Revenue Guidance for the Full Year of 2022

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Amicus Therapeutics, Inc. to Report Fiscal Year 2021 Results on Feb 24, 2022

Amicus Therapeutics, Inc. Provides Unaudited Revenue Guidance for the Year 2021 and 2022

European Medicines Agency Validates Amicus Therapeutics Marketing Authorization Applications for AT-GAA for the Treatment of Pompe Disease

Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.25 loss in 3Q 2020)

High number of new directors

Forecast to breakeven in 2023

Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.20 loss in 2Q 2020)

Amicus Therapeutics Announces European Commission Approval of Galafold® (migalastat) for Adolescents with Fabry Disease

Amicus Therapeutics Announces United Kingdom’s MHRA Grants Early Access to AT-GAA

Independent Director recently bought US$250k worth of stock

First quarter 2021 earnings released: US$0.25 loss per share (vs US$0.35 loss in 1Q 2020)

Amicus Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2021

Amicus Therapeutics, Inc. Announces Successful Pre-BLA Meeting with U.S. FDA for AT-GAA for the Treatment of Pompe Disease

Full year 2020 earnings released: US$1.07 loss per share (vs US$1.48 loss in FY 2019)

Revenue beats expectations

Amicus Therapeutics, Inc. to Report Fiscal Year 2020 Results on Mar 01, 2021

Amicus Therapeutics, Inc. Announces Topline Results of its Phase 3 PROPEL Pivotal Trial for AT-GAA

Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene Therapy At the 17Th Annual WorldSymposium™ 2021

Amicus Therapeutics Announces Presentations and Posters

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung